ArticleTherapeutic advances in gastroenterology2023

PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis.

Yoram Bouhnik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.